MX2015011466A - Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora. - Google Patents

Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.

Info

Publication number
MX2015011466A
MX2015011466A MX2015011466A MX2015011466A MX2015011466A MX 2015011466 A MX2015011466 A MX 2015011466A MX 2015011466 A MX2015011466 A MX 2015011466A MX 2015011466 A MX2015011466 A MX 2015011466A MX 2015011466 A MX2015011466 A MX 2015011466A
Authority
MX
Mexico
Prior art keywords
cardio
renoprotectora
linagliptine
antidiabetic therapy
therapy
Prior art date
Application number
MX2015011466A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Klein
Hans-Juergen Woerle
Odd-Erik Johansen
Maximilian Von Eynatten
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015011466(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2015011466A publication Critical patent/MX2015011466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2015011466A 2013-03-15 2014-03-14 Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora. MX2015011466A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159624 2013-03-15
EP13177311 2013-07-19
PCT/EP2014/055113 WO2014140284A1 (en) 2013-03-15 2014-03-14 Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Publications (1)

Publication Number Publication Date
MX2015011466A true MX2015011466A (es) 2016-01-22

Family

ID=50277246

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011466A MX2015011466A (es) 2013-03-15 2014-03-14 Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX2021014242A MX2021014242A (es) 2013-03-15 2015-09-02 Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014242A MX2021014242A (es) 2013-03-15 2015-09-02 Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.

Country Status (14)

Country Link
US (9) US20140274889A1 (cg-RX-API-DMAC7.html)
EP (4) EP4364796A3 (cg-RX-API-DMAC7.html)
JP (4) JP2016510795A (cg-RX-API-DMAC7.html)
KR (2) KR20210099201A (cg-RX-API-DMAC7.html)
CN (2) CN105188706A (cg-RX-API-DMAC7.html)
AU (2) AU2014230096C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015020209A2 (cg-RX-API-DMAC7.html)
CA (1) CA2903577C (cg-RX-API-DMAC7.html)
CL (1) CL2015002369A1 (cg-RX-API-DMAC7.html)
EA (1) EA037712B1 (cg-RX-API-DMAC7.html)
IL (1) IL240064A0 (cg-RX-API-DMAC7.html)
MX (2) MX2015011466A (cg-RX-API-DMAC7.html)
PH (1) PH12015502042A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014140284A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CN109152840A (zh) * 2016-03-28 2019-01-04 英特塞普特医药品公司 通过结合fxr激动剂和arb获得的药物
CA3022202A1 (en) * 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP3823624A1 (en) * 2018-07-17 2021-05-26 Boehringer Ingelheim International GmbH Cardiosafe antidiabetic therapy
AU2019306036B2 (en) * 2018-07-17 2025-05-15 Boehringer Ingelheim International Gmbh Cardio- and renosafe antidiabetic therapy
EP3901146A4 (en) * 2018-12-18 2022-01-19 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company PHENYLPYRROLIDINE COMPOUND AND USE THEREOF
WO2022244846A1 (ja) * 2021-05-19 2022-11-24 Kagami株式会社 細胞増殖の調整のための組成物及び細胞増殖の調整方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
MXPA03007349A (es) 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
HRP20050157B1 (en) 2002-08-21 2013-01-31 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-yl]-xanthines,the production thereof and the use of the same as medicaments
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
RS50982B (sr) 2004-02-18 2010-10-31 Boehringer Ingelheim International Gmbh. 8-[3-amino piperidin-1-il]-ksantini, njihovo dobijanje i njihova primena kao dpp-iv inhibitora
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
WO2005097798A1 (de) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel
DE102004022970A1 (de) 2004-05-10 2005-12-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2006041976A1 (en) 2004-10-08 2006-04-20 Novartis Ag Combination of organic compounds
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
BRPI0518651A2 (pt) 2004-12-24 2008-12-02 Dainippon Sumitomo Pharma composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes
JP4568361B2 (ja) * 2005-04-22 2010-10-27 アラントス・ファーマシューティカルズ・ホールディング・インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤
JP5112307B2 (ja) 2005-07-01 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害剤を合成するための方法
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1966215A1 (en) 2005-12-23 2008-09-10 Novartis AG Condensed heterocyclic compounds useful as dpp-iv inhibitors
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
UY32177A (es) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
JP2012522015A (ja) * 2009-03-27 2012-09-20 ブリストル−マイヤーズ スクイブ カンパニー Ｄｐｐ−ｉｖ阻害剤を用いて主要有害心血管事象を予防する方法
WO2011039367A2 (en) * 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Therapeutic uses of pharmaceutical compositions
CN102753161A (zh) * 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US20130303462A1 (en) * 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP2854812A1 (en) * 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada

Also Published As

Publication number Publication date
AU2019203445A1 (en) 2019-06-06
KR20210099201A (ko) 2021-08-11
KR20150128726A (ko) 2015-11-18
EA037712B1 (ru) 2021-05-13
EP3409279A1 (en) 2018-12-05
US20210205316A1 (en) 2021-07-08
PH12015502042B1 (en) 2016-01-18
US20250025470A1 (en) 2025-01-23
EP4364796A2 (en) 2024-05-08
US20200338086A1 (en) 2020-10-29
CL2015002369A1 (es) 2016-02-19
BR112015020209A2 (pt) 2017-07-18
CN110075098A (zh) 2019-08-02
MX2021014242A (es) 2022-01-06
US20240033270A1 (en) 2024-02-01
IL240064A0 (en) 2015-09-24
PH12015502042A1 (en) 2016-01-18
CA2903577A1 (en) 2014-09-18
US20180263990A1 (en) 2018-09-20
EP4364796A3 (en) 2024-07-24
AU2014230096A1 (en) 2015-08-06
JP2016510795A (ja) 2016-04-11
JP2025115998A (ja) 2025-08-07
EP2968344A1 (en) 2016-01-20
EA201500934A1 (ru) 2016-03-31
US20190192523A1 (en) 2019-06-27
JP2019112409A (ja) 2019-07-11
EP3744327A1 (en) 2020-12-02
CA2903577C (en) 2023-10-17
US20160089373A1 (en) 2016-03-31
WO2014140284A1 (en) 2014-09-18
AU2014230096C1 (en) 2019-08-29
CN105188706A (zh) 2015-12-23
US20170065596A1 (en) 2017-03-09
AU2014230096B2 (en) 2019-02-21
NZ710249A (en) 2021-04-30
JP2021095409A (ja) 2021-06-24
US20140274889A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
CR20160069A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
MX2017012553A (es) Compuestos espirociclicos.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico